We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Viatris (VTRS - Free Report) closed the most recent trading day at $15.22, moving -0.26% from the previous trading session. This change lagged the S&P 500's daily gain of 0.84%. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq added 0.1%.
Prior to today's trading, shares of the generic drugmaker had gained 1.67% over the past month. This has outpaced the Medical sector's loss of 2.97% and the S&P 500's loss of 4.03% in that time.
Viatris will be looking to display strength as it nears its next earnings release, which is expected to be February 28, 2022. The company is expected to report EPS of $0.82, down 12.77% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $4.31 billion, up 19.03% from the year-ago period.
Investors should also note any recent changes to analyst estimates for Viatris. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.59% lower. Viatris is currently a Zacks Rank #4 (Sell).
Valuation is also important, so investors should note that Viatris has a Forward P/E ratio of 4.16 right now. This valuation marks a discount compared to its industry's average Forward P/E of 23.01.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VTRS in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris (VTRS) Stock Sinks As Market Gains: What You Should Know
Viatris (VTRS - Free Report) closed the most recent trading day at $15.22, moving -0.26% from the previous trading session. This change lagged the S&P 500's daily gain of 0.84%. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq added 0.1%.
Prior to today's trading, shares of the generic drugmaker had gained 1.67% over the past month. This has outpaced the Medical sector's loss of 2.97% and the S&P 500's loss of 4.03% in that time.
Viatris will be looking to display strength as it nears its next earnings release, which is expected to be February 28, 2022. The company is expected to report EPS of $0.82, down 12.77% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $4.31 billion, up 19.03% from the year-ago period.
Investors should also note any recent changes to analyst estimates for Viatris. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.59% lower. Viatris is currently a Zacks Rank #4 (Sell).
Valuation is also important, so investors should note that Viatris has a Forward P/E ratio of 4.16 right now. This valuation marks a discount compared to its industry's average Forward P/E of 23.01.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VTRS in the coming trading sessions, be sure to utilize Zacks.com.